Novo Nordisk Haemophilia Foundation

The Novo Nordisk Haemophilia Foundation (NNHF) is a grant-making, non-profit organisation that strives to improve access to care for people with haemophilia and allied bleeding disorders in developing and emerging countries.

Haemophilia is a hereditary bleeding disorder affecting one in 10,000 people. 75% of people with haemophilia live in the developing world, where most do not have a diagnosis or access to adequate care.

 

NNHF at a glance

Objective: Address the significant need for improving care for people with haemophilia and allied bleeding disorders in developing and emerging countries.

Vision: That all people with haemophilia or allied bleeding disorders receive care and treatment wherever they live

Geographical reach: Global

Partners: Local partners and international experts    

Funded by: Novo Nordisk

Founded: 2005

Progress (as of December 2017):

  • Funded 246 programmes in 69 countries
  • Supported training over 36,000 healthcare professionals
  • Reached over 38,150 people with haemophilia and their families with educational and empowering activities
  • Diagnosed or retested over 22,750 patients

Learn more: www.nnhf.org

 

Malawi: The impact of teaming up for change

Early in 2016, while 1,600 people were expected to be living with haemophilia in Malawi, diagnosis was not possible as the country was lacking public facilities and expertise to provide diagnosis and care.